What is lpilimumab?

Ipilimumab (Ipilimumab) is an anti-cancer drug and a type of immune checkpoint inhibitor. It is a drug used to treat some malignant tumors, mainly malignant melanoma (a type of skin cancer) and advanced colorectal cancer. The mechanism of action of Ipilimumab is to enhance the immune system's attack on cancer cells by inhibiting the immune checkpoint molecule CTLA-4 (cytotoxic Tlymphocyte antigen 4).

The main function of immune checkpoint inhibitors is to relieve the immune system from suppressing cancer cells, allowing the immune system to recognize and attack cancer cells more effectively. The use of ipilimumab has shown significant anti-tumor effects in some patients, but it may also cause some immune-related adverse reactions, including immune dermatitis, immune thyroiditis, gastrointestinal reactions, etc.

Ipilimumab is usually supervised and administered by a professional medical team because it requires caution and may require management of its potential adverse effects. Treatment options and specific uses may vary based on the patient's condition and doctor's recommendations. If you or someone you know is considering ipilimumab as a cancer treatment option, it is recommended to speak with a medical professional for detailed information and advice. Note that drug information may vary from area to area and over time, so it is best to obtain the latest medical advice and information.

Ipilimumab is not currently available in China, so patients cannot purchase it domestically and can only purchase it through overseas purchase channels. There are only original drugs of Ipilimumab abroad, mainly Turkish original drugs and Bristol-Myers Squibb original drugs. The price of Turkish original drugs is around 12,000 yuan, and the specification is 50mg/10ml; Bristol-Myers Squibb's original drug costs about 11,700 yuan, and its specifications are also 50mg/10ml. The ingredients of the two drugs are the same.